Veracyte, Inc. (VCYT) stock
VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$24.23+0.22 (+0.92%)
Close on Nov 17, 2026Market cap $1.95BP/E 17.3Yield –
Veracyte r&d expenses
Research and development expenses are spending on new products and technology.
Veracyte's R&D Expenses for the twelve months ending Jun 30, 2026 was $93.37M, up 31.8% year over year. For fiscal 2025 it was $70.81M, up 2.2% from the year before. Over ten years it grew 18.7% a year on average. The highest annual figure on record is $70.81M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.81M | +2.2% |
| FY2024 | Dec 31, 2024 | $69.29M | +20.9% |
| FY2023 | Dec 31, 2023 | $57.31M | +41.1% |
| FY2022 | Dec 31, 2022 | $40.60M | +36.1% |
| FY2021 | Dec 31, 2021 | $29.84M | +73.5% |
| FY2020 | Dec 31, 2020 | $17.20M | +15.8% |
| FY2019 | Dec 31, 2019 | $14.85M | +0.2% |
| FY2018 | Dec 31, 2018 | $14.82M | +6.8% |
| FY2017 | Dec 31, 2017 | $13.88M | -9.4% |
| FY2016 | Dec 31, 2016 | $15.32M | +19.8% |
| FY2015 | Dec 31, 2015 | $12.80M | +30.5% |
| FY2014 | Dec 31, 2014 | $9.80M | +25.5% |
| FY2013 | Dec 31, 2013 | $7.81M | +18.2% |
| FY2012 | Dec 31, 2012 | $6.61M | -1.1% |
| FY2011 | Dec 31, 2011 | $6.68M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $29.44M | +81.0% |
| Q1 FY2026 | Mar 31, 2026 | $27.10M | +52.9% |
| Q4 FY2025 | Dec 31, 2025 | $20.85M | +8.1% |
| Q3 FY2025 | Sep 30, 2025 | $15.98M | -9.1% |
| Q2 FY2025 | Jun 30, 2025 | $16.26M | -1.2% |
| Q1 FY2025 | Mar 31, 2025 | $17.72M | +11.0% |
| Q4 FY2024 | Dec 31, 2024 | $19.29M | +3.3% |
| Q3 FY2024 | Sep 30, 2024 | $17.57M | +31.9% |
| Q2 FY2024 | Jun 30, 2024 | $16.47M | +31.3% |
| Q1 FY2024 | Mar 31, 2024 | $15.97M | +25.0% |
| Q4 FY2023 | Dec 31, 2023 | $18.67M | +65.4% |
| Q3 FY2023 | Sep 30, 2023 | $13.32M | +23.7% |
| Q2 FY2023 | Jun 30, 2023 | $12.54M | +33.7% |
| Q1 FY2023 | Mar 31, 2023 | $12.77M | +39.3% |
| Q4 FY2022 | Dec 31, 2022 | $11.29M | +10.1% |
| Q3 FY2022 | Sep 30, 2022 | $10.77M | +34.6% |
| Q2 FY2022 | Jun 30, 2022 | $9.38M | +50.1% |
| Q1 FY2022 | Mar 31, 2022 | $9.17M | +71.8% |
| Q4 FY2021 | Dec 31, 2021 | $10.25M | +123.5% |
| Q3 FY2021 | Sep 30, 2021 | $8.01M | +98.1% |
| Q2 FY2021 | Jun 30, 2021 | $6.25M | +49.9% |
| Q1 FY2021 | Mar 31, 2021 | $5.34M | +21.1% |
| Q4 FY2020 | Dec 31, 2020 | $4.59M | +3.2% |
| Q3 FY2020 | Sep 30, 2020 | $4.04M | +11.0% |
| Q2 FY2020 | Jun 30, 2020 | $4.17M | +25.2% |
| Q1 FY2020 | Mar 31, 2020 | $4.41M | +28.3% |
| Q4 FY2019 | Dec 31, 2019 | $4.44M | +42.2% |
| Q3 FY2019 | Sep 30, 2019 | $3.64M | +6.6% |
| Q2 FY2019 | Jun 30, 2019 | $3.33M | -27.6% |
| Q1 FY2019 | Mar 31, 2019 | $3.44M | -6.5% |
| Q4 FY2018 | Dec 31, 2018 | $3.13M | -2.4% |
| Q3 FY2018 | Sep 30, 2018 | $3.42M | +12.2% |
| Q2 FY2018 | Jun 30, 2018 | $4.60M | +27.7% |
| Q1 FY2018 | Mar 31, 2018 | $3.68M | -8.8% |
| Q4 FY2017 | Dec 31, 2017 | $3.20M | -10.8% |
| Q3 FY2017 | Sep 30, 2017 | $3.05M | -24.0% |
| Q2 FY2017 | Jun 30, 2017 | $3.60M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.03M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.59M | – |
| Q3 FY2016 | Sep 30, 2016 | $4.01M | – |
See a number that looks wrong?